X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Abbott India with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ACTAVIS (US) - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   ACTAVIS
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ACTAVIS
Dec-14
ABBOTT INDIA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs6,01517,672-   
Low Rs3,70710,779-   
Sales per share (Unadj.) Rs1,236.93,182.2-  
Earnings per share (Unadj.) Rs122.2-397.1-  
Cash flow per share (Unadj.) Rs129.0292.0-  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.26,902.2-  
Shares outstanding (eoy) m21.25265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.94.5 87.9%   
Avg P/E ratio x39.8-35.8 -111.1%  
P/CF ratio (eoy) x37.748.7 77.4%  
Price / Book Value ratio x9.32.1 452.5%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2963,782,610 2.7%   
No. of employees `0003.021.6 13.7%   
Total wages/salary Rs m3,3700-   
Avg. sales/employee Rs Th8,891.839,173.9 22.7%   
Avg. wages/employee Rs Th1,140.00-   
Avg. net profit/employee Rs Th878.3-4,888.5 -18.0%   
INCOME DATA
Net Sales Rs m26,284846,156 3.1%  
Other income Rs m504-2,112 -23.9%   
Total revenues Rs m26,789844,045 3.2%   
Gross profit Rs m3,665108,701 3.4%  
Depreciation Rs m144183,224 0.1%   
Interest Rs m826,689 0.0%   
Profit before tax Rs m4,017-103,324 -3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,579 0.0%   
Tax Rs m1,421-5,312 -26.8%   
Profit after tax Rs m2,596-105,591 -2.5%  
Gross profit margin %13.912.8 108.6%  
Effective tax rate %35.45.1 688.0%   
Net profit margin %9.9-12.5 -79.2%  
BALANCE SHEET DATA
Current assets Rs m14,446445,816 3.2%   
Current liabilities Rs m4,725325,131 1.5%   
Net working cap to sales %37.014.3 259.3%  
Current ratio x3.11.4 223.0%  
Inventory Days Days5158 88.6%  
Debtors Days Days2066 29.5%  
Net fixed assets Rs m1,113103,324 1.1%   
Share capital Rs m2130-   
"Free" reserves Rs m10,8080-   
Net worth Rs m11,0761,835,282 0.6%   
Long term debt Rs m0961,724 0.0%   
Total assets Rs m16,2413,363,468 0.5%  
Interest coverage x497.0-2.9 -17,307.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.60.3 643.3%   
Return on assets %16.0-2.3 -683.6%  
Return on equity %23.4-5.8 -407.4%  
Return on capital %36.3-3.0 -1,207.0%  
Exports to sales %0.60-   
Imports to sales %12.60-   
Net fx Rs m-3,6590-   
CASH FLOW
From Operations Rs m2,514145,302 1.7%  
From Investments Rs m-800-347,907 0.2%  
From Financial Activity Rs m-803195,474 -0.4%  
Net Cashflow Rs m912-7,132 -12.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare ABBOTT INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ABBOTT INDIA With: SHASUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  PFIZER  TORRENT PHARMA  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 21, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS